This event presents a unique and invaluable opportunity for a high-level discussion on enhancing European life science competitiveness. At the event we will explore the opportunities we have in Europe with production and investments from leading global life science companies but also the implications of Europe's lagging position in global life science innovation, including the loss of investments, tax revenue, jobs, and access to innovative treatments. We will discuss strategies to bolster the EU's competitiveness and achieve the goals of the European Health Union and the European economic security strategy.

Background:

The pharmaceutical industry is a cornerstone of Europe's strength, significantly contributing to the EU's trade balance with a value of €538 billion in 2022. This sector invests €44.5 billion in research and development annually and provides over 2.7 million jobs, enhancing societal health and driving economic growth.

Roche in Europe employs more than 44.000 talented individuals, representing 43% of our global workforce. Additionally, over 40% of Roche's global R&D investment is concentrated in Europe, amounting to €6 billion in 2022. Roche is also a significant player in manufacturing, with 7 of our 23 major production sites located in Europe.

However, Europe faces a growing competitiveness challenge. Regions like the US and China are attracting more life science investments, clinical trials, and advanced manufacturing opportunities, leaving Europe behind. In 2002, the R&D investment gap between the US and Europe was €2 billion, but by 2020, this gap had widened to nearly €25 billion.